Erythropoietin and systemic hypertension

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Pharmacology

Background:

• Systemic hypertension is a frequent complication in patients receiving recombinant human erythropoietin (r-HuEPO).
• Hypertension can manifest early or late in the course of r-HuEPO treatment, impacting both systolic and diastolic pressures.
• In hemodialysis patients with hypotension, r-HuEPO typically increases blood pressure by 10% without altering hypotensive episode frequency.

Purpose of the Study:

• To identify risk factors associated with hypertension development or exacerbation during r-HuEPO therapy.
• To explore the potential mechanisms underlying r-HuEPO-induced hypertension in hemodialysis patients.

Main Methods:

• Review of reported cases and clinical data on patients treated with r-HuEPO.
• Analysis of factors correlating with blood pressure changes.
• Investigation of proposed pathophysiological mechanisms including viscosity, vasodilation, neurohumoral activation, and direct vascular effects.

Main Results:

• Identified risk factors include pre-existing hypertension, rapid hematocrit increase, low baseline hematocrit, high/IV r-HuEPO doses, native kidneys, genetic predisposition, and younger age.
• Potential mechanisms involve increased blood viscosity, loss of hypoxic vasodilation, neurohumoral system activation, and direct vascular effects.
• Direct vascular effects may stem from increased cell calcium uptake, altered vasoactive agents (e.g., ET-1), mitogenic effects, and platelet-dependent mechanisms.

Conclusions:

• r-HuEPO therapy is associated with a significant incidence of hypertension, influenced by multiple patient-specific and treatment-related factors.
• Understanding these risk factors and underlying mechanisms is crucial for managing blood pressure in patients undergoing r-HuEPO treatment.
• Further research into the direct vascular effects may elucidate specific therapeutic targets for preventing or mitigating r-HuEPO-induced hypertension.